**Eli Lilly Unveils $6 Billion Manufacturing Facility in Huntsville, Alabama**
Eli Lilly and Co. is set to make the largest private industrial investment in Alabama’s history with the development of a $6 billion pharmaceutical manufacturing facility in Huntsville. The project forms a key part of the company’s broader plan to invest over $50 billion in expanding operations across the United States. Construction is slated to begin in 2025 and is expected to be completed by 2032.
The new facility will be constructed on a 250-acre site in the Greenbrier South area of Huntsville, located near Interstate 565 in Limestone County. This advanced manufacturing site will focus on producing the company’s first oral, small-molecule GLP-1 receptor agonist. Eli Lilly intends to submit this potential obesity treatment, called orforglipron, to global regulatory agencies later this year.
The development is projected to generate significant employment opportunities, including approximately 450 permanent positions for engineers, scientists, operations staff, and laboratory technicians. Additionally, the facility will create around 3,000 construction jobs through the building phase.
The Greenbrier South location was handpicked from a pool of more than 300 potential sites. Factors influencing the decision included its proximity to the HudsonAlpha Institute for Biotechnology and the area’s strong bioscience ecosystem.
This historic project reinforces Huntsville’s growing status as a national hub for biotech and pharmaceutical innovation.
